Abstract
Aim:
To investigate the effects of allisartan, a new angiotensin II type 1 (AT1) receptor antagonist, on blood pressure (BP) and end-organ damage (EOD) in hypertensive rats and dogs.
Methods:
First, a single dose of allisartan was given intragastrically to evaluate the BP reduction in spontaneously hypertensive rats (SHRs), two kidney-one clip (2K1C) renovascular hypertensive rats and dogs, and Beagle dogs with angiotensin II-induced hypertension. Second, allisartan was mixed in rat chow for long-term treatment. After 4 months of drug administration, rats were instrumented to determine BP and baroreflex sensitivity (BRS). Observation of morphologic changes was used to estimate EOD. Third, the acute toxicity of allisartan was compared with that of losartan in mice.
Results:
BP was significantly decreased after intragastric administration of allisartan in SHRs, 2K1C rats, 2K1C dogs and Beagle dogs with angiotensin II-induced hypertension. Compared with the control, SHRs that received long-term treatment with allisartan exhibited an improved BRS and organ protective effects. Mice who were administered allisartan experienced less acute toxicity than those treated with losartan.
Conclusion:
Allisartan is highly effective for BP reduction and organ protection with low toxicity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM . Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.
Hirose H, Saito I . Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. Hypertens Res 2003; 26: 717–22.
Dzau VJ . Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–52.
Zhang C, Hein TW, Wang W, Kuo L . Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322–9.
Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28–32.
Rakugi H, Ogihara T . The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension. Nippon Rinsho 1999; 57: 1141–7.
Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211–7.
Munafo A, Christin Y, Nussberger J, Shum LY, Borland RM, Lee R J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513–21.
Stearns RA, Chakravarty PK, Chen R, Chiu SH . Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207–15.
Shen FM, Xie HH, Ling G, Xu LP, Su DF . Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. Acta Pharmacol Sin 2005; 26: 1303–8.
Pang H, Wen YY, Ma N, Wang YT, Shi L . Protective role of a novel erythrocyte-derived depressing factor on blood vessels of renovascular hypertensive rats. Clin Exp Pharmacol Physiol 2007; 34: 393–8.
Hashimoto Y, Ohashi R, Minami K, Narita H . Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol 1999; 81: 63–72.
Liu AJ, Ma XJ, Shen FM, Liu JG, Chen H, Su DF . Arterial baroreflex: a novel target for preventing stroke in rat hypertension. Stroke 2007; 38: 1916–23.
Zhang W, Liu AJ, Yi-Ming W, Liu JG, Shen FM, Su DF . Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 83–8.
Hayakawa H, Raij L . The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997; 29: 235–41.
Zhang HG, Li XH, Zhou JZ, Liu Y, Jia Y, Yuan ZB, et al. G(alphaq)-protein carboxyl terminus imitation polypeptide GCIP-27 attenuates cardiac hypertrophy in vitro and in vivo. Clin Exp Pharmacol Physiol 2007; 34: 1276–81.
Miao CY, Xie HH, Wang JJ, Su DF . Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23: 713–20.
Shen FM, Wang J, Ni CR, Yu JG, Wang WZ, Su DF . Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors. Clin Exp Pharmacol Physiol 2007; 34: 702–7.
Smyth HS, Sleight P, Pickering GW . Reflex regulation of arterial pressure during sleep in man: a quantitative method of assessing baroreflex sensitivity. Circ Res 1969; 24: 109–21.
Luepker RV, Arnett DK, Jacobs DR Jr, Duval SJ, Folsom AR, Armstrong C, et al. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med 2006; 119: 42–9.
Bansal D, Chahoud G, Smith ES, Mehta JL . Prevention of heart failure. Curr Opin Cardiol 2006; 21: 510–6.
Tocci G, Sciarretta S, Volpe M . Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477–86.
Zoungas S, Asmar RP . Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol 2007; 34: 647–51.
Neal B, MacMahon S, Chapman N . Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–64.
Xie HH, Miao CY, Liu JG, Su DF . Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol. Acta Pharmacol Sin 2002; 23: 1199–204.
Su DF, Miao CY . Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709–15.
Shan ZZ, Dai SM, Su DF . Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertens ive rats. Am J Physiol 1999; 277: H1200–6.
Su DF, Maio CY . Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 2005; 26: 388–90.
Trippodo NC, Frohlich ED . Similarities of genetic (spontaneous) hypertension: man and rat. Circ Res 1981; 48: 309–19.
Zhou X, Frohlich ED . Analogy of cardiac and renal complications in essential hypertension and aged SHR or L-NAME/SHR. Med Chem 2007; 3: 61–5.
Shiono K, Sokabe H . Renin-angiotensin system in spontaneously hypertensive rats. Am J Physiol 1976; 231: 1295–9.
Wang X, Aukland K, Iversen BM . Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy. J Cardiovasc Pharmacol 1996; 28: 833–41.
Iversen BM, Sekse I, Ofstad J . Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 1987; 252: F480–F486.
Martinez-Maldonado M . Pathophysiology of renovascular hypertension. Hypertension 1991;17: 707–19.
Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD . Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13: 170–6.
Acknowledgements
This study was supported by grants from the National Natural Science Foundation of China (No 30672456, 30730106) and the National Hi-Technology Research & Development Programme (project 863, No 2006AA02Z4C1).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wu, My., Ma, Xj., Yang, C. et al. Effects of allisartan, a new AT1 receptor blocker, on blood pressure and end-organ damage in hypertensive animals. Acta Pharmacol Sin 30, 307–313 (2009). https://doi.org/10.1038/aps.2009.11
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2009.11
Keywords
This article is cited by
-
Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats
BMC Pharmacology and Toxicology (2021)
-
Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage
Acta Pharmacologica Sinica (2021)
-
Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent
Acta Pharmacologica Sinica (2021)
-
Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial
Advances in Therapy (2020)
-
Role of vascular KATP channels in blood pressure variability after sinoaortic denervation in rats
Acta Pharmacologica Sinica (2011)
